Heart Failure

Semaglutide exhibited a 57% reduction in major adverse cardiovascular events compared to tirzepatide in patients with CVD with no prior history of diabetes.

Despite not lowering cardiovascular death or worsening heart failure, composite data did suggest the efficacy of in-hospital initiation of SGLT2 inhibitors.

A lower incidence of all-cause mortality and hospitalization for worsening heart failure proved digitoxin’s noninferiority in this phase 4 trial.

A recap 8 clinical trials in cardiovascular care to know from the European Society of Cardiology Congress 2025.

Cohosts Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, sit down with Javed Butler, MD, to discuss the results of this major trial.

With positive topline phase 2 results, parent company Crinetics Pharmaceuticals, Inc., has announced plans to begin phase 3 testing in the second half of 2025.

Finerenone reduced diuretic needs while improving outcomes across various diuretic therapies.

Semaglutide 2.4 mg use was linked to lower medical costs and inpatient resource utilization among patients with overweight or obesity and heart failure.

A recent study from Korea has drawn connections between sleep duration and regularity and major adverse cardiovascular events.

This study suggests a causative role of left bundle branch block (LBBB) in patients’ progression to heart failure.

ACHIEVE trial data showed spironolactone 25 mg did not reduce cardiovascular mortality and hospitalization due to heart failure in dialysis patients.

The TITRATE-HF study highlights the importance of early and intensive use of guideline-recommended medical therapy, focusing on dose titration.

The updated recommendations encourage both patients and clinicians to take a more proactive approach to preventing or managing hypertension.

The 2 organizations released a joint statement on challenging the common view of HF as an inevitability and prioritizing preventive measures.

Over 11,000 bottles have been voluntarily recalled in response to a consumer complaint of a foreign substance inside a tablet, later identified as aluminum.

July delivered 9 impactful advancements across the gamut of disciplines in cardiology.

Panelists discuss differentiators between nsMRA and steroidal MRAs in the context of heart failure.

Panelists offer perspective on the role of finerenone in combination therapy approaches in patients with HFmrEF/HFpEF.

Finerenone's FDA approval marks a transformative step in heart failure treatment, offering early benefits and broad applicability.

Finerenone's FDA approval marks a breakthrough in heart failure treatment, significantly reducing cardiovascular events and hospitalizations for patients.

Combination therapy results in an overall reduction in 1-year mortality and hospitalizations compared to patients receiving SGLT2 inhibitors alone.

A recent study has suggested the efficacy of a common type 2 diabetes treatment in improving cardiac structure and metabolic control.

Fudim discusses his experiences in prescribing GLP-1 receptor agonists, as well as his opinions regarding remote patient monitoring.

An audio recap of the top 5 stories in healthcare news from the week of 07/07-07/13.

Finerenone gains FDA approval for heart failure treatment, offering new hope for patients with reduced ejection fraction and improving care options.